BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD Inc., announced today the successful closing of its previously announced acquisition of VerdaGenix, LLC, owner and operator of the Ancient Extracts USA wellness platform. With the closing complete, Ancient Extracts USA becomes a wholly owned subsidiary of BFCH, adding an established operating wellness platform featuring active direct-to-consumer infrastructure, commercial operations, proprietary formulations, intellectual property, supplier relationships, inventory, fulfillment capabilities, digital marketing systems, customer acquisition infrastructure, and a diversified catalogue of more than 20 wellness SKUs already commercialized and in market.
Management believes the acquisition represents a defining milestone in the Company’s evolution into a scalable operating platform focused on wellness, performance, functional products, and human optimization. The transaction follows a series of major strategic developments completed by BFCH over the past year, including the elimination of more than $2 million in legacy convertible debt obligations, strengthening of the Company’s balance sheet and governance infrastructure, restoration of disclosure compliance, acquisition of the EVERMIND™ intellectual property platform, expansion of executive leadership, and continued execution of the Company’s broader long-term operating strategy.
Management stated that the Company is now actively transitioning Ancient Extracts into a broader commercialization and expansion phase focused on scaling both direct-to-consumer operations and retail distribution opportunities. BFCH confirmed that it is advancing strategic growth capital initiatives designed to support inventory expansion, operational scaling, customer acquisition, retail channel development, and broader commercialization execution as the platform continues expanding. The Company believes the completion of the acquisition significantly de-risks its broader operating strategy by establishing an active commercial foundation upon which future growth initiatives can now be accelerated. With operating infrastructure, products, customer acquisition systems, and commercialization capabilities already in place, the Company’s focus is shifting toward securing and deploying strategic growth capital intended to fuel expanded distribution, customer acquisition, inventory scaling, retail penetration, operational infrastructure, and broader long-term platform expansion initiatives.
John P. Gorst, Chief Executive Officer of BFCH, stated: “We are not attempting to create a concept from scratch. Ancient Extracts already has operating infrastructure, commercialized products, existing customers, active distribution channels, and a brand foundation capable of meaningful expansion. Just as importantly, we believe the products themselves resonate strongly with consumers and are aligned with major long-term trends surrounding wellness, performance, and human optimization. Our focus now is execution, commercialization scale, and building a significantly larger operating platform around assets we believe possess real long-term value.”
Jordan P. Balencic, D.O., Chairman and Chief Science Officer of BFCH, added: “Closing Ancient Extracts represents a transformational milestone for BFCH and UNLOCKD. We believe we are still in the early stages of building what can become a much larger operating platform centered around wellness, performance, functional products, cognitive health, and human optimization. Our focus now shifts from corporate restructuring and platform assembly toward commercialization, operational execution, strategic expansion, and long-term value creation.”
The Company also confirmed that management continues actively evaluating additional acquisition opportunities, strategic partnerships, operating assets, and commercialization initiatives aligned with its broader long-term strategy. Separately, the Company recently received a formal legal opinion from securities counsel concluding that BFCH is not a shell company under Rule 405 of the Securities Act of 1933 based upon the Company’s operating strategy, asset base, acquisitions, and ongoing operational activities.
